JPWO2019217684A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019217684A5
JPWO2019217684A5 JP2020563439A JP2020563439A JPWO2019217684A5 JP WO2019217684 A5 JPWO2019217684 A5 JP WO2019217684A5 JP 2020563439 A JP2020563439 A JP 2020563439A JP 2020563439 A JP2020563439 A JP 2020563439A JP WO2019217684 A5 JPWO2019217684 A5 JP WO2019217684A5
Authority
JP
Japan
Prior art keywords
bound
drug
quencher
amount
surrogate peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020563439A
Other languages
English (en)
Japanese (ja)
Other versions
JP7570925B2 (ja
JP2021523367A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/031524 external-priority patent/WO2019217684A1/en
Publication of JP2021523367A publication Critical patent/JP2021523367A/ja
Publication of JPWO2019217684A5 publication Critical patent/JPWO2019217684A5/ja
Priority to JP2024177293A priority Critical patent/JP2025011208A/ja
Application granted granted Critical
Publication of JP7570925B2 publication Critical patent/JP7570925B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020563439A 2018-05-10 2019-05-09 インビボ受容体占有率を決定するためのアッセイ Active JP7570925B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024177293A JP2025011208A (ja) 2018-05-10 2024-10-09 インビボ受容体占有率を決定するためのアッセイ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862669442P 2018-05-10 2018-05-10
US62/669,442 2018-05-10
PCT/US2019/031524 WO2019217684A1 (en) 2018-05-10 2019-05-09 Assay to determine in vivo receptor occupancy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024177293A Division JP2025011208A (ja) 2018-05-10 2024-10-09 インビボ受容体占有率を決定するためのアッセイ

Publications (3)

Publication Number Publication Date
JP2021523367A JP2021523367A (ja) 2021-09-02
JPWO2019217684A5 true JPWO2019217684A5 (enExample) 2022-04-22
JP7570925B2 JP7570925B2 (ja) 2024-10-22

Family

ID=66821369

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020563439A Active JP7570925B2 (ja) 2018-05-10 2019-05-09 インビボ受容体占有率を決定するためのアッセイ
JP2024177293A Withdrawn JP2025011208A (ja) 2018-05-10 2024-10-09 インビボ受容体占有率を決定するためのアッセイ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024177293A Withdrawn JP2025011208A (ja) 2018-05-10 2024-10-09 インビボ受容体占有率を決定するためのアッセイ

Country Status (7)

Country Link
US (2) US12085564B2 (enExample)
EP (1) EP3791183B1 (enExample)
JP (2) JP7570925B2 (enExample)
KR (2) KR20250021652A (enExample)
CN (2) CN113804873B (enExample)
ES (1) ES2992942T3 (enExample)
WO (1) WO2019217684A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250021652A (ko) 2018-05-10 2025-02-13 브리스톨-마이어스 스큅 컴퍼니 생체내 수용체 점유율을 결정하기 위한 검정
CN115932261B (zh) * 2022-08-15 2025-07-25 广州医科大学附属第五医院 一种btk受体占有率的检测方法
CN116482345B (zh) * 2023-06-16 2023-09-22 军科正源(北京)药物研究有限责任公司 用于检测双靶点药物受体占有率的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062255A1 (en) * 2007-08-17 2009-03-05 Thallion Pharmaceuticals Inc. Tumor-targeting evaluation methodology and compounds related thereto
WO2012010240A1 (en) * 2010-07-19 2012-01-26 Cellzome Ag In vivo method for the evaluation of a compound-target interaction
EP3033625B1 (en) * 2013-08-13 2020-01-22 The Scripps Research Institute Cysteine-reactive ligand discovery in proteomes
WO2016100593A1 (en) * 2014-12-17 2016-06-23 Pharmacyclics Llc Methods and assays for quantification and normalization of kinase and ligand binding
KR20250021652A (ko) 2018-05-10 2025-02-13 브리스톨-마이어스 스큅 컴퍼니 생체내 수용체 점유율을 결정하기 위한 검정

Similar Documents

Publication Publication Date Title
Van Gool et al. Analytical techniques for multiplex analysis of protein biomarkers
Wang et al. Competitive immunoassays for the detection of small molecules using single molecule arrays
JP2021182010A (ja) Peg化分析物特異的結合剤を用いた粒子に基づくイムノアッセイ
JP5606438B2 (ja) 抗血管新生療法を受容可能な被験体の同定
Zhao et al. Rapid quantitation of human epididymis protein 4 in human serum by amplified luminescent proximity homogeneous immunoassay (AlphaLISA)
JP4700626B2 (ja) 分子上のエピトープの免疫検出のための試薬、キット及び方法
Kukova et al. Comparison of urine and plasma biomarker concentrations measured by aptamer-based versus immunoassay methods in cardiac surgery patients
Klukova et al. Glycoprofiling as a novel tool in serological assays of systemic sclerosis: A comparative study with three bioanalytical methods
Dou et al. DNA-mediated strand displacement facilitates sensitive electronic detection of antibodies in human serums
JP2011528798A (ja) 抗血管形成療法のモニター
Baroni et al. A false positive case of high-sensitivity cardiac troponin in a patient with acute chest pain: Analytical study of the interference
JPWO2019217684A5 (enExample)
KR20100074743A (ko) 초고속 스크리닝용 단백질칩 시스템을 이용한 항체모방 펩타이드 탐색방법
JP2021529948A (ja) 自己抗体の直接イムノアッセイ測定法
AU2017229495B2 (en) Immunoassay controls and the use thereof
EP2883051A1 (en) Immunoassay-based determination of in-solution binding kinetics
JPWO2011099435A1 (ja) Ku86とその自己抗体との複合体の免疫測定方法、それに用いるキット及びそれを用いた癌判定方法
Freudenberg et al. Non-invasive, ultra-sensitive, high-throughput assays to quantify rare biomarkers in the blood
JP2008507686A (ja) リウマチ様関節炎(ra)のためのバイオマーカー
Sun et al. A microsphere-based duplex competitive immunoassay for the simultaneous measurements of aldosterone and testosterone in small sample volumes: validation in human and mouse plasma
JP2009517667A5 (enExample)
JP7068323B2 (ja) 少なくとも2種のペグ化された分析物特異的結合剤を使用する免疫アッセイ
Lee et al. Development of a multiplex bead-based method for the microquantitation of δ-catenin
Lee et al. Non-invasive molecular barcode assay for diagnosis of sex hormones correlated with precocious puberty
US20200018750A1 (en) Methods and compositions for the prediction and treatment of focal segmental glomerulosclerosis